M&A / Deals Angelini inks $4.1B Catalyst buy to enter US rare disease market BioSpaceCatalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.Rare DiseaseRead full story pharminent May 7, 2026 (Last updated: May 7, 2026) BioSpace Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Bayer plans filings for cardiac amyloidosis imaging agentNext: Novo’s CEO champions “record-breaking start” for Wegovy pill in US market Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
